Cholesterol ManagementMar 15, 2026
In controlled trials, the side effects people report while taking Zetia (ezetimibe) occur at nearly the same rates as those taking placebo. That's a genuinely unusual profile for a cholesterol-lowering medication. The most common complaints, things like stomach pain and joint aches, land around 3% of patients, which is essentially what happens when you give people nothing at all.
That doesn't mean Zetia is risk-free, especially when paired with a statin. But the overall safety picture is cleaner than most people expect.
Cholesterol ManagementMar 15, 2026
In pooled trials covering more than 112,000 person-years of follow-up, pravastatin produced no cases of clinical myositis or rhabdomyolysis, and its rate of liver enzyme elevations was identical to placebo. That's a remarkably clean safety profile for a drug millions of people take daily. It doesn't mean side effects don't happen, but the large-scale evidence puts pravastatin among the better-tolerated statins available.
That said, "well-tolerated on average" doesn't always match your individual experience. Here's what the trial data actually shows about what you might feel, what's worth monitoring, and what's genuinely rare.
Cholesterol ManagementMar 15, 2026
Most people think of HDL as the "good cholesterol" and assume more is better. But the protein that makes HDL work, apolipoprotein A1 (ApoA1), tells a more complicated story. Research shows that both very low and very high levels of ApoA1 are linked to increased mortality, creating a U-shaped risk curve that challenges the simple "higher is healthier" assumption. Even more striking: ApoA1 can become oxidized inside arterial plaques, flipping from a protective molecule into one that actively promotes inflammation.
This shift in understanding, from how much ApoA1 you have to how well it actually functions, is reshaping how researchers think about cardiovascular risk and treatment.
Cholesterol ManagementMar 15, 2026
Rosuvastatin at just 10 mg lowers LDL cholesterol by roughly 45% on average. That's a significant drop from what's technically classified as a "moderate-intensity" dose, and it puts this single pill in striking distance of higher-dose regimens that come with more side effect concerns. But the story doesn't end at cholesterol numbers. The same research that confirms rosuvastatin's potency also flags real risks around kidney health, diabetes, and genetic vulnerabilities that most people never hear about.
What makes 10 mg a particularly interesting dose is its versatility. It sits at a sweet spot: strong enough to be a workhorse for high-risk patients, low enough to combine with other drugs for even deeper LDL cuts, and capped as the maximum recommended dose for people with advanced kidney disease. Understanding where it shines and where it stumbles matters if you're taking it or considering it.
Cardiovascular HealthMar 15, 2026
Icosapent ethyl (sold as Vascepa) is not your standard fish oil supplement. It's a prescription, purified form of EPA, one specific omega-3 fatty acid, and at 4 grams per day on top of statin therapy, it reduced major cardiovascular events by roughly 25% in high-risk patients. That's a striking number for a drug added to an already-optimized regimen. But the benefit comes with a trade-off that doesn't always make it into the headline: a measurable increase in atrial fibrillation risk.
The story of icosapent ethyl is really a story about residual risk, the cardiovascular danger that persists even after you've gotten your LDL cholesterol under control with a statin. For the right patient, this drug addresses that gap in a way few other add-on therapies have managed.
Cardiovascular HealthMar 15, 2026
Praluent (alirocumab) can cut LDL cholesterol by roughly 60% in patients already taking the highest tolerated statin dose. That alone is striking. But the more compelling finding is what happens next: in a trial of nearly 19,000 people who had recently suffered a heart attack or acute coronary event, that LDL drop translated into a 15% reduction in major cardiovascular events, including heart attack, stroke, and cardiovascular death. The catch is that not everyone gets the same payoff. Where your LDL starts and whether you have diabetes dramatically change the math.
Praluent is a subcutaneous injection, not a pill. It belongs to a class called PCSK9 inhibitors, and it's approved specifically as an add-on for adults with familial hypercholesterolemia or established cardiovascular disease who need more LDL lowering than statins alone can deliver. This isn't a first-line treatment. It's the next step when statins aren't getting the job done.
Blood TestsMar 15, 2026
Your LDL cholesterol could come back "normal" while the number of dangerous particles in your blood tells a completely different story. An apolipoprotein B (apoB) blood test measures the actual count of artery-clogging particles rather than just the cholesterol riding inside them. Research consistently shows that this particle count is often a stronger predictor of coronary artery disease and heart attack than LDL cholesterol alone, especially in people with diabetes, obesity, or high triglycerides.
That gap between what LDL-C shows and what apoB reveals matters most for people who think their lipid numbers look fine. It's also the reason guidelines in Europe and Canada already include apoB treatment targets, and why the test is gaining traction in clinical practice.
Cardiovascular HealthMar 15, 2026
Repatha (evolocumab) drops LDL cholesterol by roughly 50 to 60 percent on top of whatever therapy you're already on. That's a striking number, especially for people who've already maxed out on statins and lifestyle changes. It also translates into a 15 to 20 percent relative reduction in major cardiovascular events like heart attacks and strokes.
But this isn't a first-line treatment you'd pick up at the pharmacy alongside a multivitamin. Repatha is a subcutaneous injection reserved for specific high-risk groups: people with established cardiovascular disease, familial hypercholesterolemia, or those who genuinely can't tolerate statins. Understanding where it fits, and where it doesn't, matters.
Digestive DisordersMar 15, 2026
Psyllium, the single ingredient in Metamucil, has clinical trial evidence behind four distinct health outcomes: relieving constipation, lowering LDL cholesterol, improving blood sugar control in type 2 diabetes, and supporting modest weight loss. That makes it one of the best-studied fiber supplements you can buy.
The catch is that these results consistently require around 10 grams per day or more, taken for at least several weeks. A single spoonful on a random Tuesday morning probably isn't doing much.
Cardiovascular HealthMar 13, 2026
Autopsy and imaging studies find atherosclerotic lesions in the thoracic aorta in the majority of adults. Most of them had no idea anything was building up. Atherosclerosis of the aorta, the progressive accumulation of fatty, inflammatory plaque inside the wall of the body's largest artery, is one of the most common vascular conditions in existence. It is also one of the quietest.
That silence is the problem. By the time aortic atherosclerosis causes symptoms, it has often already contributed to a stroke, an aneurysm, or a clot that traveled somewhere it shouldn't. Understanding where this disease starts, how it progresses, and what actually drives it gives you a real chance to intervene before it reaches that point.
Cholesterol ManagementMar 13, 2026
A lower dose of a statin paired with ezetimibe can deliver the same cardiovascular protection as cranking the statin dose to maximum, while causing fewer muscle complaints, less diabetes risk, and better long-term adherence. That's the core finding from large randomized trials and meta-analyses comparing these two strategies head to head.
If you've been told you need a statin but worry about tolerability, or if you're already on a high dose and struggling with side effects, this combination approach is worth understanding. The evidence is strong enough that it's reshaping how clinicians think about lipid-lowering therapy, especially for older adults and people prone to statin-related problems.
Cholesterol ManagementMar 13, 2026
Across multiple human studies, including randomized trials, long-term treatment data, and post-surgical follow-ups, atorvastatin does not appear to cause weight gain. That is not a hedged, "maybe-maybe-not" conclusion. It is a consistent finding that shows up in different patient populations, at different doses, and over different timeframes. If the number on your scale is climbing while you take atorvastatin, the research strongly suggests something else is responsible.
This matters because statins are among the most widely prescribed drugs in the world, and weight concerns are one of the reasons people consider stopping them. The evidence available gives a clear picture worth understanding.
